Showing results (321-330 of 582) with videos related to
Sort By:
Pageof 59
Journal of the Neurological Sciences|July 19, 2011
Efficacy and safety of incobotulinumtoxinA (NT 201, XEOMIN®, botulinum neurotoxin type A, without accessory proteins) in patients with cervical dystoniaCynthia L Comella, Joseph Jankovic, Daniel D Truong, et al.The Journal of Neuropsychiatry and Clinical Neurosciences|June 17, 2011
Transcutaneous electrical stimulation (TENS) for psychogenic movement disordersJoseph Ferrara, William Stamey, Adriana M Strutt, et al.Journal of Neurochemistry|July 24, 2010
Proteasome inhibition modeling nigral neuron degeneration in Parkinson's diseaseWenjie Xie, Xuping Li, Chao Li, et al.Neurology and Therapy|May 23, 2015
Effect of tetrabenazine on motor function in patients with huntington diseaseJoseph M Ferrara, Giovanni Mostile, Christine Hunter, et al.Movement Disorders : Official Journal of the Movement Disorder Society|October 10, 2003
Treatment of hypophonia with collagen vocal cord augmentation in patients with parkinsonismAmy N Hill, Joseph Jankovic, Kevin D A T Vuong, et al.Journal of the Neurological Sciences|July 3, 2007
Distinguishing psychogenic and essential tremorChristopher Kenney, Alan Diamond, Nicte Mejia, et al.Experimental Neurology|December 14, 2004
Age-dependent dopaminergic dysfunction in Nurr1 knockout miceChuantao Jiang, Xinhua Wan, Yi He, et al.Journal of the Neurological Sciences|February 14, 2018
The nosology of tardive syndromesKaren Frei, Daniel D Truong, Stanley Fahn, et al.Movement Disorders Clinical Practice|October 27, 2018
SPG11 Mutations Associated With a Complex Phenotype Resembling Dopa-Responsive DystoniaSubhashie Wijemanne, Joshua M Shulman, Joohi Jimenez-Shahed, et al.Movement Disorders : Official Journal of the Movement Disorder Society|June 12, 2008
Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assayMitchell F Brin, Cynthia L Comella, Joseph Jankovic, et al.Pageof 59